Prevention of Prostate Cancer Morbidity and Mortality: Primary Prevention and Early Detection

Medical Clinics of North America

Volumn 101, Issue 4, 2017, Pages 787-806

  Barry, Michael J ^a   Simmons, Leigh H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Prostate cancer; Prostate specific antigen; Screening; Shared decision making

Indexed keywords

DUTASTERIDE; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ANTIGEN DETECTION; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CASE STUDY; CAUSE OF DEATH; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DECISION SUPPORT SYSTEM; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DIETARY INTAKE; DIGITAL RECTAL EXAMINATION; EARLY CANCER DIAGNOSIS; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; GENERAL HOSPITAL; HEALTH CARE QUALITY; HUMAN; INFORMED CONSENT; LUNG CANCER; MASSACHUSETTS; MEDICOLEGAL ASPECT; MORBIDITY; OVARY CANCER; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SURGERY; RANDOMIZATION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SHARED DECISION MAKING; TREND STUDY; URINE INCONTINENCE; AGE; ANCESTRY GROUP; BLOOD; DIET; GENETIC PREDISPOSITION; LIFESTYLE; MALE; MORTALITY; PROCEDURES; PROSTATIC NEOPLASMS; STANDARDS; TIME FACTOR; WATCHFUL WAITING;

AGE FACTORS; BIOMARKERS, TUMOR; CONTINENTAL POPULATION GROUPS; DIET; DIGITAL RECTAL EXAMINATION; EARLY DETECTION OF CANCER; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIFE STYLE; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; WATCHFUL WAITING;

EID: 85020940467     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2017.03.009     Document Type: Review

References (92)

1. American Cancer Society, Cancer facts & figures 2016. 2016, American Cancer Society, Atlanta (GA).
2. Howlander N, Noone AM, Krapcho M, et al, editors. SEER cancer statistics review, 1975-2013. National Cancer Institute: Bethesda (MD). Available at: http://seer.cancer.gov/csr/1975_2013/. Based on November 2015 SEER data submission, posted to the SEER Web site. Accessed April 3, 2017.
3. Brawley, O.W., Prostate cancer epidemiology in the United States. World J Surg 30:2 (2012), 195–200.
4. Cancer Research UK. Prostate Cancer Statistics. Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer. Accessed November 29, 2016.
5. Gu, Q., Paulose-Ram, R., Burt, V.L., et al. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. NCHS data brief, no. 177, 2014, National Center for Health Statistics, Hyattsville (MD).
6. Raval, A.D., Thakker, D., Negri, H., et al. Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 19 (2016), 151–162.
7. Platz, E.A., Tangen, C.M., Goodman, P.J., et al. Statin drug use is not associated with prostate cancer risk in men who are regularly screened. J Urol 192 (2014), 379–384.
8. Bruner, D.W., Moore, D., Parlanti, A., et al. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer 107 (2003), 797–803.
9. Saarimaki, L., Tammela, T.L., Maattanen, L., et al. Family history in the finnish prostate cancer screening trial. Int J Cancer 136 (2015), 2172–2177.
10. Randazzo, M., Muller, A., Carlsson, S., et al. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised study of Screening for Prostate Cancer (ERSPC, Aarau). BJU Int 117 (2016), 576–583.
11. Markozannes, G., Tzoulaki, I., Karli, D., et al. Diet, body size, physical activity and risk of prostate cancer: an umbrella review of the evidence. Eur J Cancer 69 (2016), 61–69.
12. Poppel, H.V., Tombai, B., Chemoprevention of prostate cancer with nutrients and supplements. Cancer Manag Res 3 (2011), 91–100.
13. Lippman, S.M., Klein, E.A., Goodman, P.J., et al. The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301 (2009), 39–51.
14. Klein, E.A., Thompson, I.M., Tangen, C.M., et al. Vitamin E and the risk of prostate cancer: updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306 (2011), 1549–1556.
15. Thompson, I.M., Goodman, P.J., Tangen, C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003), 215–224.
16. Andriole, G.L., Bostwick, D.G., Brawley, O.W., et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362 (2010), 1192–1202.
17. Pinsky, P.F., Black, A., Grubb, R., et al. Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials. Cancer 119 (2013), 593–601.
18. Wallner, L.P., DiBello, J.R., Li, B.H., et al. 5-alpha reductase inhibitors and the risk of prostate cancer mortality in men treated for benign prostatic hyperplasia. Mayo Clin Proc 91:12 (2016), 1717–1726.
19. Catalona, W.J., Smith, D.S., Ratliff, T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991), 1156–1161.
20. National Cancer Institute. Prostate-Specific Antigen (PSA) Test. Available at: https://www.cancer.gov/types/prostate/psa-fact-sheet. Accessed November 30, 2016.
21. Chybowski, F.M., Bergstralh, E.J., Oesterling, J.E., The effect of digital rectal examination on the serum prostate specific antigen concentration: results of a randomized study. J Urol 148 (1992), 83–86.
22. Stenner, J., Holthaus, K., Mackenzie, S.H., et al. The effect of ejaculation on prostate-specific antigen in a prostate cancer-screening population. Urology 51 (1998), 455–459.
23. Mejak, S.L., Bayliss, J., Hanks, S.D., Long distance bicycle riding causes prostate-specific antigen to increase in men aged 50 years and over. PLoS One, 8(2), 2013, e56030.
24. Greiman, A., Shah, J., Bhavsar, R., et al. Six weeks of fluoroquinolone antibiotic therapy for patients with elevated serum prostate-specific antigen is not clinically beneficial: a randomized controlled clinical trial. Urology 90 (2016), 32–37.
25. Thompson, I.M., Ankerst, D.P., Chi, C., et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294 (2005), 66–70.
26. Thompson, I.M., Pauler, D.K., Goodman, P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350 (2004), 2239–2246.
27. Ankerst, D.P., Hoefler, J., Bock, S., et al. Prostate cancer prevention trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology 83 (2014), 1362–1367.
28. Roobol, M.J., van Vugt, H.A., Loeb, S., et al. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Eur Urol 61 (2012), 577–583.
29. Catalona, W.J., Partin, A.W., Slawin, K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279 (1998), 1542–1547.
30. Loeb, S., Sanda, M.G., Broyles, D.L., et al. The prostate health index selectively identifies clinically significant prostate cancer. J Urol 193 (2015), 1163–1169.
31. Loeb, S., Lilja, H., Vickers, A., Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer. Curr Opin Urol 26 (2016), 459–465.
32. Vickers, A.J., Wolters, T., Savage, C.J., et al. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol 56 (2009), 753–760.
33. Vickers, A.J., Till, C., Tangen, C.M., et al. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 103 (2011), 462–469.
34. Vickers, A.J., Thompson, I.M., Klein, E., et al. A commentary on PSA velocity and doubling time for clinical decisions in prostate cancer. Urology 83 (2014), 592–596.
35. D'Amico, A.V., Chen, M.H., Roehl, K.A., et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004), 125–135.
36. Nickel, J.C., Gilling, P., Tammela, T.L., et al. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 108 (2011), 388–394.
37. Andriole, G.L., Crawford, E.D., Grubb, R.L., et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104 (2012), 125–132.
38. Shoag, J.E., Mittal, S., Hu, J.C., Reevaluating PSA testing rates in the PLCO Trial. N Engl J Med 374 (2016), 1795–1796.
39. Taylor, K.L., Luta, G., Miller, A.B., et al. Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol 30 (2012), 2768–2775.
40. Schröder, F.H., Hugosson, J., Roobol, M.J., et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384 (2014), 2027–2035.
41. Schröder, F.H., Hugosson, J., Carlsson, S., et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 62 (2012), 745–752.
42. Auvinen, A., Moss, S.M., Tammela, T.L., et al. Absolute effect of prostate cancer screening: balance of benefits and harms by center within the European Randomized Study of Prostate Cancer Screening. Clin Cancer Res 22 (2016), 243–249.
43. Wolters, T., Roobol, M.J., Steyerberg, E.W., et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer 126 (2010), 2387–2393.
44. Bokhorst, L.P., Venderbos, L.D., Schröder, F.H., et al. Do treatment differences between arms affect the main outcome of ERSPC Rotterdam?. J Urol 194 (2015), 336–342.
45. Essink-Bot, M.L., de Koning, H.J., Nijs, H.G., et al. Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst 90 (1998), 925–931.
46. Heijnsdijk, E.A., Wever, E.M., Auvinen, A., et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 367 (2012), 595–605.
47. Rosario, D.J., Lane, J.A., Metcalfe, C., et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ, 344, 2012, d7894.
48. Wade, J., Rosario, D.J., Macefield, R.C., et al. Psychological impact of prostate biopsy: physical symptoms, anxiety, and depression. J Clin Oncol 31 (2013), 4235–4241.
49. Loeb, S., Carter, H.B., Berndt, S.I., et al. Complications after prostate biopsy: data from SEER-Medicare. J Urol 186 (2011), 1830–1834.
50. Wilt, T.J., Brawer, M.K., Jones, K.M., et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367 (2012), 203–313.
51. Hamdy, F.C., Donovan, J.L., Lane, J.A., et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375 (2016), 1415–1424.
52. Donovan, J.L., Hamdy, F.C., Lane, J.A., et al. Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. N Engl J Med 375 (2016), 1425–1437.
53. Bokhorst, L.P., Bangma, C.H., van Leenders, G.J., et al. Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Eur Urol 65 (2014), 329–336.
54. Gulati, R., Gore, J.L., Etzioni, R., Comparative effectiveness of alternative prostate-specific antigen–based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med 158 (2013), 145–153.
55. Roth, J.A., Gulati, R., Gore, J.L., et al. Economic analysis of prostate-specific antigen screening and selective treatment strategies. JAMA Oncol 2 (2016), 890–898.
56. Wolf, A.M., Wender, R.C., Etzioni, R.B., et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 60 (2010), 70–98.
57. Smith, R.A., Andrews, K., Brooks, D., et al. Cancer screening in the United States, 2016: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 66 (2016), 96–114.
58. Qaseem, A., Barry, M.J., Denberg, T.D., et al. Screening for prostate cancer: a guidance statement from the clinical guidelines committee of the American College of Physicians. Ann Intern Med 158 (2013), 761–769.
59. Basch, E., Oliver, T.K., Vickers, A., et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology provisional clinical opinion. J Clin Oncol 30 (2012), 3020–3025.
60. Carter, H.B., Albertsen, P.C., Barry, M.J., et al. Early detection of prostate cancer: AUA guideline. J Urol 190 (2013), 419–426.
61. Moyer, V.A., U.S. Preventive Services Task Force, Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157 (2012), 120–134.
62. Chou, R., Croswell, J.M., Dana, T., et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 155 (2011), 762–771.
63. Cho, H., Klabunde, C.N., Yabroff, K.R., et al. Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies. Ann Intern Med 159 (2013), 667–676.
64. Crawford, E.D., Pinsky, P.F., Chia, D., et al. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Urol 175 (2006), 1286–1290.
65. Abdollah, F., Sun, M., Sammon, J.D., et al. Prevalence of nonrecommended screening for prostate cancer and breast cancer in the United States: a nationwide survey analysis. JAMA Oncol 2 (2016), 543–545.
66. Vickers, A.J., Cronin, A.M., Björk, T., et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ, 341, 2010, c4521.
67. Schaeffer, E.M., Carter, H.B., Kettermann, A., et al. Prostate specific antigen testing among the elderly–when to stop?. J Urol 181 (2009), 1606–1614.
68. Kim, S.P., Karnes, R.J., Gross, C.P., et al. Contemporary national trends of prostate cancer screening among privately insured men in the United States. Urology 97 (2016), 111–117.
69. Catalona, W.J., Hudson, M.A., Scardino, P., et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 152 (1994), 2037–2042.
70. Powell, I.J., Banerjee, M., Novallo, M., et al. Should the age specific prostate specific antigen cutoff for prostate biopsy be higher for black than for white men older than 50 years?. J Urol 163 (2000), 146–148.
71. Rosario, D.J., Lane, J.A., Metcalfe, C., et al. Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study. Eur Urol 53 (2008), 777–784.
72. Salami, S.S., Vira, M.A., Turkbey, B., et al. Multiparametric magnetic resonance imaging outperforms the prostate cancer prevention trial risk calculator in predicting clinically significant prostate cancer. Cancer 120 (2014), 2876–2882.
73. Schoots, I.G., Roobol, M.J., Nieboer, D., et al. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol 68 (2015), 438–450.
74. Klotz, L., Vesprini, D., Sethukavalan, P., et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33 (2015), 272–277.
75. Tosoian, J.J., Mamawala, M., Epstein, J.I., et al. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol 33 (2015), 3379–3385.
76. Overholser, S., Nielson, M., Torkko, K., et al. Active surveillance is an appropriate management strategy for a proportion of men diagnosed with prostate cancer by prostate specific antigen testing. J Urol 194 (2015), 680–684.
77. Eggener, S.E., Badani, K., Barocas, D.A., et al. Gleason 6 prostate cancer: translating biology into population health. J Urol 194 (2015), 626–634.
78. Ehdaie, B., Active surveillance for prostate cancer: is it too active?. BJU Int, 118, 2016, 343.
79. Weiner, A.B., Patel, S.G., Etzioni, R., et al. National trends in the management of low and intermediate risk prostate cancer in the United States. J Urol 193 (2015), 95–102.
80. Cooperberg, M.R., Carroll, P.R., Trends in management for patients with localized prostate cancer, 1990-2013. JAMA 314 (2015), 80–82.
81. Sepucha, K.R., Fowler, F.J., Mulley, A.G., Policy support for patient-centered care: the need for measurable improvements in decision quality. Health Aff (Millwood)(Suppl Variation), 2004, VAR54–VAR62, 10.1377/hlthaff.var.54.
82. Han, P., Kobrin, S., Breen, N., et al. National evidence on the use of shared decision making in prostate specific antigen screening. Ann Fam Med 11 (2013), 306–314.
83. Hoffman, R., Couper, M., Zikmund-Fisher, B., Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS) Study. Arch Intern Med 169 (2009), 1611–1618.
84. The SHARE Approach. Essential Steps of Shared Decision Making: Quick Reference Guide (Workshop Curriculum: Tool 1). 2014. AHRQ Pub. No. 14-0034-1-EF. Available at: www.ahrq.gov/shareddecisionmaking. Accessed April 3, 2017.
85. Six Steps to Shared Decision Making. Healthwise, INC, Web. Available at: http://cdn-www.informedmedicaldecisions.org/imdfdocs/SixStepsSDM_CARD.pdf. Accessed December 3, 2016.
86. Stacey, D., Légaré, F., Col, N.F., et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev(1), 2014 CD001431.
87. Sepucha, K.R., Simmons, L.H., Barry, M.J., Ten years, forty decision aids, and thousands of patient uses: shared decision making at Massachusetts General Hospital. Health Aff 35 (2016), 630–636.
88. Wexler, R.M., Gerstein, B.S., Brackett, C., et al. Patient responses to decision aids in the United States. Intl J Pers Cent Med 5 (2015), 105–111.
89. Barry, M.J., Wexler, R.M., Brackett, C.D., et al. Responses to a decision aid on prostate cancer screening in primary care practices. Am J Prev Med 49 (2015), 520–525.
90. Merenstein, D., A piece of my mind. Winners and losers. JAMA 291 (2004), 15–16.
91. Barry, M.J., Wescott, P.H., Reifler, E.J., Reactions of potential jurors to a hypothetical malpractice suit alleging failure to perform a prostate-specific antigen test. J Law Med Ethics 36 (2008), 396–402.
92. McNaughton-Collins, M.F., Barry, M.J., One man at a time–resolving the PSA controversy. N Engl J Med 365 (2011), 1951–1953.